
US stocks weekly: Fireworks
Semiconductor index up nearly 2% ** Financials firm 2.4%. Big banks rise after Fed stress test success, clearing path for dividend hikes, share buybacks
Read moreSemiconductor index up nearly 2% ** Financials firm 2.4%. Big banks rise after Fed stress test success, clearing path for dividend hikes, share buybacks
Read moreFTSE 100 rises 0.6%, FTSE 250 adds 1.2%
*Read more(Alliance News) - The FTSE 100 and sterling rallied, while the bond market calmed on Thursday as Keir Starmer supported his chancellor, reassuring markets that a change at the Treasury wasn't on the cards.
Read moreFTSE 100 down 0.4%, FTSE 250 falls 0.4%
*Read more(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:
Read moreHassan says decision reduces access for low-income patients
*Read morePrice to be cut to below $5 per dose by 2028
*Read moreLONDON, June 25 (Reuters) - Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to $5 per dose by 2028, more than halving its current cost, they said on Wednesday.
Read more(Sharecast News) - GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Read more(Alliance News) - GSK PLC on Monday said linerixibat has been accepted for review by the European Medicines Agency for the treatment of intense itching caused by a rare autoimmune liver disease.
Read moreFTSE 100 down 0.2%, FTSE 250 adds 0.4%
*Read more(Alliance News) - London's FTSE 100 faded into the close on Friday, ending lower, as weak retail sales data and falls in heavyweight oil and drug stocks offset hopes for progress in the Israel-Iran conflict.
Read more(Alliance News) - GSK PLC on Friday announced that Japan has accepted a regulatory application to expand the use of its respiratory syncytial virus [RSV] vaccine Arexvy.
Read more(Sharecast News) - Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult population.
Read more